dichlororibofuranosylbenzimidazole has been researched along with Disease Models, Animal in 1 studies
Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Y | 1 |
| Huang, L | 1 |
| Zhu, G | 1 |
| Pei, Z | 1 |
| Zhang, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Mechanism of lncRNA NEAT1 in Alleviating Acute Respiratory Distress Syndrome Through miR-27b Regulated Nrf2 Pathway[NCT04937855] | 425 participants (Anticipated) | Observational | 2021-07-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for dichlororibofuranosylbenzimidazole and Disease Models, Animal
| Article | Year |
|---|---|
Downregulated microRNA-27b attenuates lipopolysaccharide-induced acute lung injury via activation of NF-E2-related factor 2 and inhibition of nuclear factor κB signaling pathway.
Topics: Acute Lung Injury; Animals; Antagomirs; Anti-Inflammatory Agents; Cytokines; Dichlororibofuranosylbe | 2019 |